Communications Lessons from the FDA’s Approval of Biogen’s Aduhelm
Last month, in what was instantly hailed as one of the most controversial drug approvals in decades, the FDA granted accelerated approval to Biogen’s Aduhelm, the first new Alzheimer’s treatment to receive approval in nearly 20 years.